Q3 2019 13F Holders as of 30 Sep 2019
-
Type / Class
-
Equity / SHS
-
Total 13F shares
-
6,302,684
-
Share change
-
-1,432,808
-
Total reported value
-
$30,118,780
-
Price per share
-
$4.78
-
Number of holders
-
30
-
Value change
-
-$11,278,740
-
Number of buys
-
10
-
Number of sells
-
13
Institutional Holders of GALMED PHARMACEUTICALS LTD - SHS (GLMD) as of Q3 2019
As of 30 Sep 2019,
GALMED PHARMACEUTICALS LTD - SHS (GLMD) was held by
30 institutional
shareholders
that filed Form 13F with the SEC.
Together, they reported ownership of
6,302,684 shares.
The largest 10 holders included
BVF INC/IL, 683 Capital Management, LLC, Ibex Investors LLC, Nantahala Capital Management, LLC, RAYMOND JAMES & ASSOCIATES, BAKER BROS. ADVISORS LP, FIRST MIDWEST BANK TRUST DIVISION, Knoll Capital Management, LP, ARK Investment Management LLC, and P.A.W. CAPITAL CORP.
This page lists
30
institutional shareholders reporting positions in this security
for the Q3 2019 filing period.
| Investor |
Option |
Weight % |
Change % |
Value $ |
* Price
|
Shares |
Share Change |
Activity |
Report Period |
* Reported Price is the price of the security as of the portfolio date. This value is significant in that it is the last known price at which the security was still held.
An asterisk sign (*) next to the price indicates that the price is likely invalid.